Prognostic Value of VEGF in Patients Submitted to Percutaneous Coronary Intervention

Table 1

Patients demographic, clinical, and biochemical characterization. Results are presented in median (Q25–Q75) unless otherwise specified.

Variable	Controls; (𝑛=44)	Patients; (𝑛=94)
Demographics
Male sex (𝑛, %)	28, 64	66, 70
Age (y)	58 (52–67)	62 (56–71)
Weight (kg)	72 (65–80)	76 (65–80)
Height (m)	1.6 (1.6–1.7)	1.6 (1.6–1.7)
Risk factors/comorbidities^a
Smoking (𝑛, %)	4, 9	18, 20
Obesity (𝑛, %)	25, 61	67, 74
Hypercholesterolemia (𝑛, %)	22, 50	61, 66
Arterial hypertension (𝑛, %)	17, 39	74, 80*
Diabetes mellitus (𝑛, %)	0	39, 42*
Previous medication
Aspirin (𝑛, %)	4, 9	58, 64*
ACE inhibitors (𝑛, %)	9, 21	44, 49*
Antiplatelets (𝑛, %)	0, 0	48, 52*
𝛽-Blockers (𝑛, %)	3, 7	41, 45*
Statins (𝑛, %)	10, 23	62, 68*
Diagnostic markers
CRP (mg/L)	1.6 (1–3.7)	4.3 (3.0–13.9)*
NT-ProBNP (pg/mL)	33 (11–64)	148 (53–780)*
VEGF (pg/mL)	419 (212–758)	15.9 (9.0–264)*

^aDiabetes: fasting plasma glucose concentration ≥7.0 mmol/L or 2 h plasma glucose ≥11.1 mmol/L or confirmed as clinically known and treated diabetes mellitus; hypertension: systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg or use of antihypertensive therapy; dyslipidemia: total serum cholesterol ≥190 mg/dL or serum triglycerides ≥180 mg/dL or use of lipid-lowering medication; smoking: inhaled use of cigarettes, cigars, or pipes in any quantity, in the year previous to admission.
*Significant differences to controls (𝑃≤0.01).